PP2A activator

DRUG CLASS:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

BRAF T1799A	Breast Cancer	BRAF T1799A	Breast Cancer	sorafenib + nanoliposomal ceramide Sensitive: D – Preclinical sorafenib + nanoliposomal ceramide Sensitive : D	sorafenib + nanoliposomal ceramide Sensitive: D – Preclinical sorafenib + nanoliposomal ceramide Sensitive : D
BRAF T1799A	Melanoma	BRAF T1799A	Melanoma	sorafenib + nanoliposomal ceramide Sensitive: D – Preclinical sorafenib + nanoliposomal ceramide Sensitive : D	sorafenib + nanoliposomal ceramide Sensitive: D – Preclinical sorafenib + nanoliposomal ceramide Sensitive : D

Associations(2)